. Experimental approaches to modify muscle-specific fusion programmes (related to Figure 1) 
The grey colour in PDLP LIM domain 3 indicates that it is encoded in an alternative exon. The box shows the protein sequences of the different isoforms deleted in the Pax 1 deficiency. Table S5 . Only a full length Pax isoform is able to rescue the fusion phenotype in DT1 and VA2 muscles. Furthermore, there is no maternal contribution to the fusion phenotype observed in Pax mutants.
(B) Muscle-specific misexpression of Mp20, Pax and mspo. eme-Gal4 and slou-Gal4 drivers were used to misexpress Mp20, Pax, mspo in DA1 and in DT1, VA2 and VT1 muscles respectively. Stage 15 embryos were stained with Eve and 3-Tub (DA1) or with Slou and Tm2 (DT1, VA2, VT1). The values used to plot the graphs are shown in Table S6 . Asterisks show the significance of variation compared to the wt. Mp20 gain of function increases the number of nuclei in the DA1 muscle but does not in muscles with high endogenous expression level of Mp20. Also in VT1, in which Mp20 is not expressed, its overexpression has no effect. Pax gain of function induces an increased number of nuclei in DA1, DT1 and VT1 muscles, whereas VA2 displaying a high endogenous level of Pax is not affected. In contrast, mspo gain of function leads to the reduction of the number of fusion events in DA1, DT1 and VA2 muscles. Ectopic expression of eve, lb and slou modify combinatorial code of Mp20, Pax and mspo expressions that can be correlated with a change in fusion programme. Bold outlines show the previously characterized Mp20, Pax or mspo activities in different programmes. For example, ectopic expression of eve induces DA1-specific combination of Mp20, Pax, and mspo expression levels in DT1 and VA2 muscles and leads to the switch to DA1 fusion programme (11 nuclei). Note that in the SBM in duf-Gal4;UAS-eve context, the Mp20 expression level is lower than in the wt, but a change in fusion programme is not effective. This could be due to the persistent expression of Lb in the SBM, which might be sufficient to maintain the 7 nuclei fusion programme. In the VT1 in duf-Gal4;UAS-eve context, induction of combinatorial code of Mp20, Pax and mspo specific to Eve programme does not induce the corresponding fusion programme. In this case, note that, neither mspo overexpression, nor mspo loss of function, have an effect on VT1 muscle. Similarly, ectopic Lbe expression in the VT1 induce high levels of Mp20 but doesn't modify its fusion programme most probably because Mp20 is not functional in this muscle. Furthermore, the median Pax expression level induced in Lbe gain of function context, compared to the low Pax expression level in the SBM in wt condition, doesn't affect the Lb-dependent programme of fusion because, as previously shown, Pax is not effective in this Lb-dependent programme. 
n.d. 6,88 ± 0,88 10,75 ± 1,5 10,53 ± 1,68 5,65 ± 1,25 slou-Gal4; UAS-rpr (*) n.d. 7,28 ± 0,9 2,03 ± 2,74 2,28 ± 2,98 1,08 ± 1,59 5053A-Gal4; UAS-duf (*) n.d. 7,18 ± 1,11 8,88 ± 0,88 9 ± 0,88 3,53 ± 0,68 5053A-Gal4; UAS-rpr (*) n.d. 7,05 ± 0,91 8,58 ± 0,96 8,68 ± 1,1 3,6 ± 0,71
For each genotype, the average number of nuclei  standard deviation is shown (n=30) or (n=40 in lines indicated by an asterisk). In bold, genes involved in cytoskeleton dynamics, in grey, genes identified as lb targets. For each genotype, the average number of nuclei  standard deviation is shown (n=30). 1,0 ± 0,0 1,53 ± 0,51 2,57 ± 0,63 2,93 ± 0,64 3,73 ± 0,78 duf-Gal4; UAS-lbe DA1 1,2 ± 0,41 2,0 ± 0,64 4,1 ± 0,84 5,23 ± 1,48 7,37 ± 0,89 eme-Gal4; UAS-Mp20 DA1 1,33 ± 0,61 2,53 ± 0,78 5,3 ± 1,34 9,37 ± 1,35 12,6 ± 1,45 eme-Gal4; UAS-Pax DA1 1,4 ± 0,56 2,53 ± 1,14 6,1 ± 1,56 9,83 ± 1,9 13,1 ± 1,69 eme-Gal4; UAS-mspo DA1 1,27 ± 0,64 2,03 ± 0,67 3,63 ± 1,63 6,33 ± 1,4 8,57 ± 1,61 24B-Gal4;UAS-RNAi Mp20 VA2 1,0 ± 0,0 2,2 ± 0,66 4,37 ± 0,72 5,67 ± 0,99 6,57 ± 1,04 24B-Gal4;UAS-RNAi Pax VA2 1,13 ± 0,35 2,2 ± 0,55 4,0 ± 0,83 5,87 ± 0,78 6,7 ± 0,79
For each stage and each genotype, the average number of nuclei  standard deviation is shown (n=30).
